UK and US-listed drugmaker PureTech Health (LSE: PRTC) has announced plans to return $100 million to its shareholders by way of a tender offer.
The move comes in addition to a recently completed share buyback program worth $50 million.
The latest capital return represents around 14% of the firm’s market cap, and follows an announcement that PureTech will receive $293 million from its remaining stake in Karuna Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze